

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 February 2024 (29.02.2024)



(10) International Publication Number
WO 2024/044549 A1

(51) International Patent Classification:

C07D 257/02 (2006.01) C07F 9/6524 (2006.01)
A61K 49/16 (2006.01) C07K 5/103 (2006.01)
A61K 51/10 (2006.01) C07K 16/30 (2006.01)
A61P 35/00 (2006.01) C07K 16/32 (2006.01)

(21) International Application Number:

PCT/US2023/072585

(22) International Filing Date:

21 August 2023 (21.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/373,183 22 August 2022 (22.08.2022) US

(71) Applicant: **ABDERA THERAPEUTICS INC.** [US/US];
535 Middlefield Road, Suite 240, Menlo Park, California
94025 (US).

(72) Inventors: **ABRAMS, Michael J.**; 535 Middlefield Road,
Suite 240, Menlo Park, California 94025 (US). **JUDGE,**
Adam Daniel; 535 Middlefield Road, Suite 240, Menlo


Park, California 94025 (US). **MANDEL, Alexander Lau-**
rence; 535 Middlefield Road, Suite 240, Menlo Park, Cali-
fornia 94025 (US). **VISWAS, Raja Solomon**; 535 Middle-
field Road, Suite 240, Menlo Park, California 94025 (US).

(74) Agent: **ZUNIC, Valentin**; WILSON SONSINI
GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto,
California 94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

(54) Title: VHH ANTIBODY CONJUGATES



Group mean $\pm$ SEM

FIG. 19A

(57) Abstract: Described herein are immunoconjugates comprising an: a) antigen binding region; b) an immunoglobulin heavy chain constant region; and c) a radioisotope chelating agent; wherein the molecular weight of said immunoconjugate is between 60 and 110 kDa. The immunoconjugates can be used to deliver alpha and beta emitters for the treatment of tumors or cancer.

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*